A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

Required: MS4A1 overexpression (CD20+)

histologically (laboratory test) confirmed CD20 + non-Hodgkin's lymphoma

Cannot have received: anti-PD-1 therapy

Subjects who have received anti-programmed death-ligand 1 (PD-L1), programmed cell death 1 (PD-1), or cytotoxic T-lymphocyte associated protein 4 (CTLA-4) therapy.

Cannot have received: autologous stem cell transplant

Exception: within 100 days prior to CHO-H01 therapy

Subjects who have completed an autologous stem cell transplant within 100 days prior to CHO-H01 therapy

Cannot have received: allogeneic stem cell transplant

or an allogeneic stem cell transplant

Cannot have received: radiation therapy

Exception: within 28 days prior to CHO-H01 administration

Subjects who have had radiation therapy...within 28 days prior to CHO-H01 administration.

Cannot have received: systemic corticosteroids

Exception: at a daily dose higher than 15 mg prednisone or equivalent within 14 days prior to the first administration of CHO-H01; topical, inhaled, nasal, and ophthalmic steroids are allowed

Subjects who have received (or are receiving) systemic corticosteroids: At a daily dose higher than 15 mg prednisone or equivalent within 14 days prior to the first administration of CHO-H01; Topical, inhaled, nasal, and ophthalmic steroids are allowed.

Cannot have received: live vaccination

Exception: within 28 days prior to CHO-H01 administration

Subjects who have had...live vaccinations within 28 days prior to CHO-H01 administration.